Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib (ZACTIMA) vs placebo in unresectable locally advanced or metastatic medullary thyroid cancer
2005-005077-29Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Medullary Thyroid Cancer (MTC) comparing Vandetanib (ZACTIMA) with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Aug 2006; status: completed.
02
Drugs
vandetanib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on 2005-005077-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005077-29.